Navigation Links
Transplant Surgery No Riskier at Night: Study
Date:5/31/2011

TUESDAY, May 31 (HealthDay News) -- Surgeon fatigue has been blamed for adverse outcomes among patients operated on at night, but new research finds that time of day has no effect on the survival rates of patients undergoing heart and lung transplants.

"We aren't suggesting that fatigue is good," said the study's lead author, Dr. Ashish S. Shah, an assistant professor of surgery at the Johns Hopkins University School of Medicine, in a university news release. "But what is important is that, at least in this specialty, it seems we're able to deal with it without subjecting the patient to risk."

The study, published June 1 in the Journal of the American Medical Association, compiled data on a decade of transplants across the United States involving a total of 27,118 patients. Researchers found survival rates up to one year after surgery were similar regardless of when the organ transplants were performed -- day or night.

Although researchers noted there was a slightly higher rate of airway dehiscence (a surgical complication) associated with nighttime lung transplants, total hospital length of stay was similar no matter what time of day surgeons operated.

The study's authors concluded that experienced transplant teams have probably found effective ways to cope with and overcome fatigue and emotional stress in order to do their jobs well. "It is likely that because urgent nighttime operations are common in all types of transplant surgery, health care personnel involved in the transplant have developed various systems to prevent errors and directly cope with the limitations associated with nighttime medical care," they wrote in the news release.

The researchers also argued that surgeons from other specialties could reduce adverse patient outcomes by copying the strategies and coping techniques used by heart and lung transplant teams.

"The authors provide us with firm evidence that even highly complex procedures can be performed safely and with good results at any time during the day," said Dr. Ernesto P. Molmenti, vice chairman of surgery and director of the transplant program at the North Shore-LIJ Health System in Manhasset, N.Y., who was not involved in the study.

"We should consider the performance quality guidelines of cardiothoracic transplant centers as a way to improve other medical and surgical outcomes," Molmenti concluded.

More information

The U.S. National Institutes of Health provides more information on heart transplant survival rates.

-- Mary Elizabeth Dallas

SOURCE: Ernesto P. Molmenti, M.D., vice chairman of surgery and director, transplant program, North Shore-LIJ Health System in Manhasset, N.Y.; Johns Hopkins Medicine, news release, May 31, 2011.


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New drug for kidney transplant recipients effective in humans
2. WellPoint/Blue Cross Liver Transplant Denial Trial Starts Monday
3. Spanish Only, Please: Special Latino Clinic Launched For Potential Abdominal Transplant Patients
4. WellPoint/Blue Cross Liver Transplant Denial Trial Begins Today, Illustrates Need for Toughening of White House Reform Plan
5. Newer cornea transplant surgery shows short- and long-term promise
6. Cristophe Salon in Beverly Hills Teams Up with Mad Men Actor to Help Raise Money for His 17-Year-Old Cousins Heart Transplant
7. Two Babies Born a Year Apart After Ovary Transplant
8. Wounded Soldier Who Received Historic Cell Transplant Gets Standing Ovation at Diabetes Research Institute Benefit
9. Internal Anthem Blue Cross/WellPoint Document: Only Patients Who Push Back Get Covered Out of State Liver Transplants
10. Drug dramatically reduces nausea and vomiting in bone marrow transplant patients
11. Kidney Patients From Across South Carolina Visit State Capitol to Encourage Policies that Improve Patient Access to Life-Saving Dialysis and Transplant Care
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Transplant Surgery No Riskier at Night: Study 
(Date:5/26/2017)... ... , ... “When the Stars Lead Home”: a poignant story of loss, determination, ... Weigel Douglas, an avid reader who lives in the Pacific Northwest with her husband, ... Hills Adventure Camp. She couldn’t be more grateful. , Twelve-year old Tizzy could not ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... recipient of proceeds from its 14th Annual Clays for Kids fundraiser, to be ... 30, Bennett, Colorado. , As part of BluSky’s partnership with The Adoption ...
(Date:5/26/2017)... ... ... “Cactus Jack: Against All Odds”: the story of Coach Cactus Jack and ... Odds” is the creation of published author, Walter Hubbard, a retired wildlife and fisheries ... child Jane. Walter. Walter and Jane have three adult children and a granddaughter. ...
(Date:5/24/2017)... BELLEVILLE, N.J. (PRWEB) , ... May 24, 2017 ... ... joined Clara Maass Medical Center CEO Mary Ellen, hospital employees, and town officials ... in Belleville. , The facility was developed by Rendina as part of its ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD ... New York City. He is known for his distinguished expertise and experience in the ... Benvenisty holds sub-specialty training in treating renovascular disease and aortic aneurysm . He ...
Breaking Medicine News(10 mins):
(Date:5/26/2017)... , May 25, 2017  In response to ... , Direct Relief is working with Pfizer to ... available at no cost to community health centers, free ... providers nationwide. "Pfizer has a long-standing ... medicines and ensuring patient safety through educational activities," said ...
(Date:5/22/2017)... 2017  Lilac Corp, the company that sells ... of a new website . The website ... clinical study that showed surprising clearance of the ... individuals suffering from HPV warts, precancerous, or cancerous ... no other treatments that clear the virus. Specifically, ...
(Date:5/18/2017)... May 17, 2017  Bayer announced today that the ... be presented at the 53 rd Annual Meeting ... place June 2-6 in Chicago . ... span prostate, colorectal, liver and thyroid cancers, as well ... Phase II CHRONOS-1 trial of copanlisib in patients with ...
Breaking Medicine Technology: